Samsung Electronics is partnering with global clinical specialist Alcedis to leverage biometric data collected from its Galaxy Watch in drug development clinical trials.
On June 23, Samsung announced the agreement with Alcedis, a data-driven digital clinical trial company, to initiate clinical trials for drug development using everyday health data.
Founded in 1992, Alcedis is a German digital clinical trial company and a subsidiary of the global healthcare AI firm Huma. It has over 30 years of experience conducting clinical trials in various fields, including oncology, cardiology, and neurology.
Through this collaboration, the two companies aim to expand the application of wearable technology from daily health management to medical research.
They will jointly develop methods to convert biometric data collected in real-life environments via the Galaxy Watch into clinical indicators for evaluating the efficacy and safety of new drugs.
Additionally, they plan to collaborate extensively across the entire clinical research process, from data collection to participant monitoring, trial operations, and regulatory compliance.
Choi Jong-min, Senior Vice President of Samsung Electronics' MX Business Health Development Group, stated, "Clinical research is advancing towards a deeper understanding of human health through the collaboration of various partners with technological and scientific expertise. We have supported researchers with various development tools, including the Samsung Health SDK, and through this collaboration, we aim to ensure that everyday data translates into innovative drug development research and benefits for patients."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.